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Abstract
Background:  Recent studies relating to the association between DNA repair-gene
polymorphisms and colorectal cancer risk would, to the best of our knowledge, appear to be very
limited. This study was designed to examine the polymorphisms associated with three DNA repair
genes, namely: XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln, and investigate their
role as susceptibility markers for colorectal cancer.
Methods: We conducted a case-control study including 727 cases of cancer and 736 hospital-
based age- and sex-matched healthy controls to examine the role of genetic polymorphisms of
three DNA-repair genes (XRCC1, XRCC3 and XPD) in the context of colorectal cancer risk for the
Taiwanese population. Genomic DNA isolated from 10 ml whole blood was used to genotype
XRCC1 Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln by means of polymerase chain reaction
(PCR) and restriction fragment length polymorphism (RFLP) analysis.
Results: The risk for colorectal cancer did not appear to differ significantly amongst individuals
featuring the XRCC1 399Arg/Arg genotype (OR = 1.18; 95% CI, 0.96–1.45), the XRCC3 241Thr/Thr
genotype (OR = 1.25; 95% CI, 0.88–1.79) or the XPD 751Gln allele (OR = 1.20; 95% CI, 0.90–1.61),
although individuals featuring a greater number of risk genotypes (genotype with OR greater than
1) did experience a higher risk for colorectal cancer when compared to those who didn't feature
any risk genotypes (Trend test P = 0.03). Compared with those individuals who didn't express any
putative risk genotypes, individuals featuring all of the putative risk genotypes did experience a
significantly greater cancer risk (OR = 2.43, 95% CI = 1.21–4.90), particularly for individuals
suffering tumors located in the rectum (OR = 3.18, 95% CI = 1.29–7.82) and diagnosed prior to
the age of 60 years (OR = 4.90, 95% CI = 1.72–14.0).
Conclusions: Our results suggest that DNA-repair pathways may simultaneously modulate the
risk of colorectal cancer for the Taiwanese population, and, particularly for rectal cancer and
younger patients.
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Background
Humans are routinely exposed to mutagenic and carcino-
genic aromatic amines via smoking, well-cooked food and
other sources [1]. These chemicals can form DNA adducts
in vivo and thus lead to DNA damage [2]. The integrity of
most of the so-damaged DNAs is typically restored as a
consequence of the action of certain DNA-repairing
enzymes, the normal function of which is important for
maintaining genomic integrity and preventing cellular
neoplastic transformation [3]. Since the genetic polymor-
phisms of DNA-repair enzymes might be able to influence
DNA adduct levels [4-6], the particular degree of DNA-
repair capacity has often been associated with the risk of
human cancers [7-11].
Amongst the known genetic polymorphisms of the DNA-
repair genes [12], the xeroderma pigmentosum group D
(XPD, also known as ERCC2) and x-ray repair cross-com-
plementing groups 1 and 3 (XRCC1 and XRCC3) have
been studied most commonly [13]. The XPD  gene
encodes a helicase that is a component of the transcrip-
tion factor TFIIH [14], this factor being an essential mem-
ber of the nucleotide-excision repair (NER) pathway that
is responsible for effecting repairs to bulky adducts and
UV-induced DNA damage [15]. In 2002, Qiao et al. [16]
reported that individuals featuring XPD 751Gln/Gln did
demonstrate suboptimal DNA-repair capacity (DRC) in
regard to its ability to remove UV photoproducts when
compared to the XPD 751Lys/Lys and Lys/Gln genotypes.
The XRCC1 protein is a scaffolding protein directly asso-
ciated with polymerase beta, DNA ligase III and poly
(ADP-ribose) polymerase (PARP) and functions in a com-
plex to facilitate the base-excision repair (BER) and single-
strand break-repair processes [17-19]. In 1999, Lunn et al.
noted that individuals harboring the XRCC1  399Gln
allele were associated, more significantly, with higher lev-
els of both aflatoxin B1-DNA adducts and glycophorin A
variants when compared to individuals who exhibited the
Arg/Arg genotype [4]. XRCC3 participates in DNA double-
strand break repair and is a member of an emerging family
of Rad-51-related proteins that likely participate in
homologous recombinational repair (HRR) in order to
maintain chromosome stability [20].
To the best of our knowledge, studies pertaining to these
DNA-repair genes focusing on colorectal cancer risk
would appear to be limited and controversial. In 2000,
Abdel-Rahman et al. [21] observed that the XRCC1
399Gln allele, compared to the XRCC1 399Arg/Arg geno-
type, was associated with an increased risk for developing
colorectal cancer, especially amongst young urban resi-
dents, although in 2003, Mort et al. [22] failed to reveal
any significant associations between colorectal cancer risk
and any polymorphisms of four of the NER genes (XPD,
XPF, XPG, ERCC1) or XRCC1. In the present paper, we
conducted a hospital-based case-controlled study to
examine the role of genetic polymorphisms of three DNA-
repair genes (XRCC1, XRCC3 and XPD) in the context of
colorectal cancer risk for the Taiwanese population.
Methods
Subjects
Detailed descriptions of the specific characteristics of the
study participants have been published previously [23]. In
brief, participants were recruited from the Chang Gung
Memorial Hospital between January 1995 and January
1999 inclusively. The colorectal adenocarcinoma cancer
cases (n = 776) participating in this study were newly diag-
nosed and histologically confirmed. Patients suffering
from familial adenomatous polyposis, hereditary non-
polyposis colorectal cancer, or inflammatory bowel dis-
ease and other related malignancies were excluded from
study participation. Seven hundred and twenty-seven of
the original 776 cases (94%) were finally included in this
study. Seven hundred and forty-seven age (same age) and
sex-matched controls were recruited from the Physical
Check-Up Department during the same period. All the
participating controls had received comprehensive health
examinations including colonoscopies. After excluding
individuals diagnosed with other colorectal diseases, a
history of other cancers or the existence of a family history
of colorectal cancer, 736 controls (98%, 736/747) were
finally included in this study. With informed consent, the
socio-demographic characteristics of study participants
were ascertained by means of the application of a struc-
tured questionnaire, at which time 10 ml of venous blood
was collected.
Genotyping
Genomic DNA isolated from 10 ml whole blood was used
to genotype XRCC1 Arg399Gln, XRCC3 Thr241Met and
XPD Lys751Gln by means of polymerase chain reaction
(PCR) and restriction fragment length polymorphism
(RFLP) analysis. All of the PCR reactions were carried out
by a Mastercycler gradient thermocycler (Eppendorf,
Hamburg, Germany) in a final volume of 25 ul containing
200 ng of each primer, 50 ng genomic DNA, 1.5 mM
MgCl2, 200 ul dNTPs and 1.0 unit of Taq DNA Polymer-
ase in the buffer provided by the manufacturer. In addi-
tion, all laboratory genotyping personnel were blind to
the case-control status of the samples.
The 615 bp XRCC1 PCR products were amplified with the
primers 5'-TTGTGCTTTCTCTGTGTCCA-3' (sense) and 5'-
TCCTCCAGCCTTTTCTGATA-3' (antisense) and digested
with MspI (New England BioLabs, Beverly, MA, USA). The
Arg allele revealed 374 and 221 bp fragments following
digestion and polyacrylamide gel electrophoresis, whilst
the Gln allele was not digested by MspI [4]. The 136 bp
XRCC3 PCR products were amplified with the primers 5'-BMC Cancer 2005, 5:12 http://www.biomedcentral.com/1471-2407/5/12
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GCCTGGTGGTCATCGACTC-3' (sense) and 5'-
ACAGGGCTCTGGAAGGCACTGCTCAGCTCACGCACC-
3' (antisense) and digested with NcoI (New England
BioLabs). The Met allele revealed 97 and 39 bp fragments
following digestion and polyacrylamide gel electrophore-
sis, while the Thr allele was not digested by NcoI [24]. The
734 bp XPD PCR products were amplified with the prim-
ers 5'-CCTCTCCCTTTCCTCTGTTC-3' (sense) and 5'-
CAGGTGAGGGGGACATCT-3' (antisense) and digested
with PstI (Takara, Japan). The Gln allele revealed 646 and
88 bp fragments following digestion and polyacrylamide
gel electrophoresis, whilst the Lys allele was not able to be
digested by PstI [25].
Statistical analysis
Tests for Hardy-Weinberg equilibrium amongst controls
were conducted using observed genotype frequencies and
a chi-square test featuring one degree of freedom. Baseline
sociodemographic characteristics between cases and con-
trols were analyzed using the chi-square test and two-sam-
ple Students' t-test. Multivariate unconditional logistic
regressions were used to examine the association between
the XRCC1, XRCC3 and XPD genotypes and the risk for
colorectal cancer. Since the differences in the estimated
risks between conditional logistical regression and uncon-
ditional logistical regression were small, unconditional
logistical regression was used to estimate odds ratio (OR)
and 95% confidence interval (CI) with the matching fac-
tors (age and gender) included in the model for estima-
tion [26]. Other potential confounders (such as physical
activity, cigarette smoking, alcohol use, coffee intake, and
consumption of staple, meat, vegetable/fruit and fish/
shrimp) would be also included if they have >10% effect
on the gene main effects. However, none of these factors
have met the inclusion criteria.
Based on the multiplicative scale, the likelihood ratio test
was further used to evaluate the interaction between
XRCC1, XRCC3 and XPD genes on the risk for the colorec-
tal cancer. Since the associations between polymorphisms
of DNA-repair gene, cancer susceptibility and DNA repair
capacity are inconsistent [13], we defined the risk allele as
the allele with OR>1 observed in the present study. Strat-
ified analyses were also conducted to evaluate the differ-
ences between specific tumor sites (colon and rectum)
and age groups (< = 60 years old and > 60 years old). All
analyses were performed using the SAS statistical package
(version 8.1 for windows; SAS Institute, Inc., Cary, NC,
USA) and all tests were two-sided.
Results
More men (56%) than women participated in this study
(Table 1). The mean age for both groups was 60 years.
From the cancer cases, 352 patients suffered from colon
cancer (48%) and 375 patients from rectal cancer (52%),
with most such cases being deemed to be at stage II or
stage III (both were 33%). Detailed analyses of the socio-
demographic characteristics and potential risk factors
associated with colorectal cancer amongst the study pop-
ulation have been published previously [23].
The genotypic distributions of the three DNA-repair genes
for both cancer cases and controls are shown in Table 2.
The frequencies for the XRCC1 399Gln, XRCC3 241Met
and XPD 751Gln allele amongst the controls were, respec-
tively, 0.27, 0.05 and 0.07, these genotype frequencies
being in Hardy-Weinberg equilibrium. Due to the rela-
tively low frequencies of variant alleles for these genes in
the present study, any genotype featuring one or more var-
iant alleles was combined for further analyses. The risk for
colorectal cancer was not significantly different for
individuals featuring the XRCC1  399Arg/Arg genotype
Table 1: Characteristic details for the cases and controls
Variables Cases, n (%) (N = 727) Control, n (%) (N = 736) p
Gender 0.75a
Male 410 (0.56) 409 (0.56)
Female 317 (0.44) 327 (0.44)
Mean age (SD), years 60.3 (12.8) 60.7 (13.0) 0.64b
Colon/rectum, N 352/375 -
Stage
09  ( 1 . 2 ) -
I 84 (11.6) -
II 242 (33.3) -
III 241 (33.2) -
IV 151 (20.8) -
a: Chi-square test
b: t testBMC Cancer 2005, 5:12 http://www.biomedcentral.com/1471-2407/5/12
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(OR = 1.18; 95% CI, 0.96–1.45), the XRCC3 241Thr/Thr
genotype (OR = 1.25; 95% CI, 0.88–1.79) or the XPD
751Gln allele (OR = 1.20; 95% CI, 0.90–1.61).
As revealed in Table 3, those individuals exhibiting a
greater number of risk genotypes (genotype with OR
greater than 1) faced a greater risk for colorectal cancer
when compared to those individuals who did not display
any risk genotypes (Trend test, P = 0.03). Subjects who
demonstrated two or three of the putative risk genotypes
did reveal a significantly greater risk for colorectal cancer
(OR = 1.95; 95% CI, 1.08–3.52 and OR = 2.43; 95% CI,
1.21–4.90, respectively) as compared to those individuals
who did not feature any putative risk genotypes, although
it appears that no gene-gene interactions arose amongst
these three genes (all P levels for interaction were >0.21).
When stratified by tumor site and age at diagnosis, these
combined gene effects upon cancer risk were observed for
Table 2: Distribution of three DNA repair genes for cases and controls
Polymorphism Cases, n (%) Control, n (%) OR (95% CI) a
XRCC1 Arg399Gln
Arg/Arg 407 (56.7) 384 (52.7) 1.00
Arg/Gln 260 (36.2) 291 (39.9) 0.84 (0.67–1.07)
Gln/Gln 51 (7.1) 54 (7.4) 0.82 (0.53–1.25)
Missing 9 7
With Glnb 311 (43.3) 345 (47.3) 1.00
Arg/Arg 407 (56.7) 384 (52.7) 1.18 (0.96–1.45)
XRCC3 Thr241Met
Thr/Thr 660 (91.5) 658 (89.7) 1.00
Thr/Met 60 (8.3) 74 (10.1) 0.83 (0.56–1.21)
Met/Met 1 (0.1) 2 (0.3) 0.50 (0.05–5.51)
Missing 6 2
With Metc 61 (8.5) 76 (10.4) 1.00
Thr/Thr 660 (91.5) 658 (89.7) 1.25 (0.88–1.79)
XPD Lys751Gln
Lys/Lys 602 (84.0) 631 (86.3) 1.00
Lys/Gln 112 (15.6) 96 (13.1) 1.29 (0.94–1.76)
Gln/Gln 3 (0.4) 4 (0.6) 0.81 (0.18–3.62)
Missing 10 5
Lys/Lys 602 (84.0) 631 (86.3) 1.00
With Glnd 115 (16.0) 100 (13.7) 1.20 (0.90–1.61)
a: ORs and 95% CIs were estimated from unconditional logistic regressions, controlling for age and gender
b: Arg/Gln+ Gln/Gln
c: Thr/Met+ Met/Met
d: Lys/Gln+ Gln/Gln
Table 3: Combined effect of XRCC1, XRCC3 and XPD genes upon colorectal cancer risk
XRCC1 Arg399Gln XRCC3 Thr241Met XPD Lys751Gln Cases Controls OR (95% CI)a OR (95% CI)a
With Gln With Met Lys/Lys 18 34 1.00 1.00
Arg/Arg With Met Lys/Lys 30 30 1.91 (0.89–4.10)
With Gln Thr/Thr Lys/Lys 239 257 1.77 (0.97–3.22) 1.79 (0.99–3.24)
With Gln With Met With Gln 6 6 1.90 (0.54–6.76)
Arg/Arg Thr/Thr Lys/Lys 312 307 1.93 (1.07–3.50)
Arg/Arg With Met With Gln 7 5 2.65 (0.74–9.56) 1.95 (1.08–3.52)
With Gln Thr/Thr With Gln 48 46 1.99 (0.99–4.01)
Arg/Arg Thr/Thr With Gln 54 42 2.43 (1.21–4.90) 2.43 (1.21–4.90) 0.03b
a: ORs and 95% CIs were estimated from unconditional logistic regressions, controlling for age and gender
b: Trend testBMC Cancer 2005, 5:12 http://www.biomedcentral.com/1471-2407/5/12
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individuals who revealed that their tumor was located in
the rectum (Trend test P = 0.03) and those individuals for
whom their tumor was diagnosed prior to their being 60
years of age (Trend test P = 0.004; Table 4). The ORs for
subjects with three putative risk genotypes were 3.18
(95% CI, 1.29–7.82) for rectal cancer and 4.90 (95% CI,
1.72–14.0) for those individuals diagnosed prior to 60
years of age, respectively.
Discussion
To the best of our knowledge, few studies have investi-
gated the role of polymorphisms in DNA-repair genes for
patients suffering colorectal cancer [21,22]. In this hospi-
tal-based case-control study of colorectal cancer-suffering
patients in Taiwan, we found polymorphisms in three
DNA-repair genes associated with an elevated risk of
colorectal cancer. In addition, a gene-dosage effect was
found for rectal cancer and younger patients. These find-
ings suggest that those genes involved in different DNA-
repair pathways may act simultaneously in the process of
carcinogenesis for colorectal cancer.
Although we didn't find any significant independent asso-
ciations between these DNA-repair genes and colorectal
cancer risk, the risk appeared to be slightly increased for
individuals who featured the XRCC1 399Arg/Arg, XRCC3
241Thr/Thr genotypes and the XPD 751Gln allele. Our
results do not appear to be entirely consistent with the
results of some previous reports [21,22], the former group
reporting that the XRCC1  399Gln allele significantly
increased the risk of colorectal cancer (OR = 3.98, 95% CI
= 1.50–10.6). In 2003, Mort et al. [22] noted that the risk
of suffering colorectal cancer was significantly heightened
for individuals who featured the XRCC3  241Thr allele
(OR = 1.52, 95% CI = 1.04–2.22) and only slightly
increased for those individuals who revealed the XRCC1
399Gln and XPD 751Gln alleles. In 2001, Park et al. [27]
reported that advanced colorectal cancer-suffering
patients who revealed the XPD 751Gln/Gln genotype fea-
tured a poorer (positive) response rate to chemotherapy
and also a shorter survival period compared with colorec-
tal cancer-suffering individuals who belonged to either
the 751Lys/Lys or the 751Lys/Gln group.
The apparent divergence between these studies and ours
might be due to one of two reasons. Firstly, it may simply
be that ethnic differences in allele frequency for the poly-
morphism might explain the controversial findings. The
frequencies for the XRCC1 399Gln, XRCC3 241Met and
XPD 751Gln alleles amongst the healthy controls in this
study (0.27, 0.05 and 0.07, respectively) were similar to
the results for other studies conducted in Taiwan [28,29]
and China [30,31], but appeared to be much lower than
those reported in 2003 by Mort et al. [22] (0.42 for XRCC1
399Gln, 0.45 for XRCC3  241Met and 0.36 for XPD
751Gln) for a British population. On the other hand, the
Table 4: Number of risk-genotypes of three DNA repair genes and colorectal cancer risk by age at diagnosis and by tumor site
Number of risk-genotypes*
0123P b
Age at diagnosis
< = 60 years
Cases/Controls 7/20 114/126 169/155 29/17
OR 1.0 2.58 3.12 4.90 0.004
(95% CI)a (reference) (1.05–6.33) (1.28–7.58) (1.72–14.0)
>60 years
Cases/Controls 11/14 161/167 198/203 25/25
OR 1.0 1.24 1.25 1.28 0.74
(95% CI)a (reference) (0.55–2.82) (0.55–2.83) (0.49–3.35)
Tumor site
Colon
Cases/Controls 10/34 132/293 177/358 23/42
OR 1.0 1.51 1.65 1.86 0.16
(95% CI)a (reference) (0.72–3.14) (0.80–3.42) (0.78–4.44)
Rectum
Cases/Controls 8/34 143/293 190/358 31/42
OR 1.0 2.13 2.32 3.18 0.03
(95% CI)a (reference) (0.96–4.73) (1.05–5.11) (1.29–7.82)
*Risk-genotype was defined as genotype with OR>1 as shown in Table 3.
a: ORs and 95% CIs were estimated from unconditional logistic regressions, controlling for age and gender
b: p for trend testBMC Cancer 2005, 5:12 http://www.biomedcentral.com/1471-2407/5/12
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XRCC1 399Gln allele frequency observed in the present
study is greater than that observed by Abdel-Rahman et al.
in 2000 (0.14 for XRCC1 399Gln) [21]. Abdel-Rahman et
al. also found that urban residents have 9.97-fold
increased risk of early-onset colorectal carcinoma than
rural residents with the XRCC1 399Gln allele [21]. There-
fore, it is possible that the divergence in results from dif-
ferent studies might be related to different levels of
carcinogen exposure for different populations. Moreover,
inadequate study design such as a too-small sample size
and/or the inadequate controlling for certain confounders
(such as age and gender) should also be considered as
constituting the underpinning for such differing results.
Combined effects of polymorphisms of the XRCC1
Arg399Gln,  XRCC3  Thr241Met and XPD  Lys751Gln
genes in regard to colorectal cancer risk were observed in
the present study. With the complexity of detail of envi-
ronmental exposures to various carcinogens, it is plausi-
ble that the effective repair of DNA damaged by chemical
mixtures necessitates multiple DNA-repair pathways
(including BER, HRR and NER pathways). The failure of,
or the presence of deficient DNA repair capacity for each
specific DNA-repair pathway may contribute to an
increase in cancer risk. Additive or multiplicative effects of
combined genetic variants for different DNA-repair path-
ways have been previously reported for lung cancer [32],
melanoma [33] and breast cancer [34]. In 2003, Zhou et
al. [35] found that the risk of lung cancer amongst non-
smokers increased progressively with the increase in the
number of high-risk alleles of XRCC1 and XPD genes. Hu
et al. [36] also observed that prolonged cell-cycle delay
was significantly associated with the number of variant
alleles of the APE1 and XRCC1 genes that were present. It
would therefore appear reasonable to hypothesize that
genetic polymorphism(s) for DNA-repair genes may
simultaneously contribute to colorectal cancer
susceptibility.
In this study, we found that the combined effect of multi-
ple DNA-repair genes upon colorectal cancer risk was sig-
nificant for our younger age group, but not so for the older
age group. This finding appears to be similar to the results
of most of the previous studies pertaining to colorectal
cancer [21], basal-cell carcinoma [37], head-and-neck
cancer [38], hepatocellular carcinoma [39], and lung can-
cer [6,32,35,40] that we reviewed, although we did note
that one study reported that such an elevated risk was also
observed for old-aged head-and-neck cancer patients [41].
In addition, few studies that we reviewed failed to find a
difference between age groups in regard to for cancer risk
[31,42-46]. In 2000, Duell et al. [47] noted that old
healthy subjects who featured the XRCC1 399Gln allele
appeared to be significantly associated with detectable
DNA adducts in their blood mononuclear cells when
compared to younger subjects who featured the 399Arg/
Arg genotype. In 2001, Hemminki et al. [48] also found
that old subjects who revealed the XPD 751Gln/Gln gen-
otype exhibited a decreased DNA-repair rate for, specifi-
cally, UV-specific cyclobutane pyrimidine dimers in the
skin. Therefore, it is possible that individuals who demon-
strate a less-efficient DNA-repair capacity might develop
tumors at a younger age than individuals who reveal an
efficient DNA-repair capacity.
In our study, we also found that the combined genetic
effect of these three DNA-repair genes in regard to cancer
risk was more pronounced for the rectum than for the
colon. This difference may reflect certain etiological differ-
ences between colon and rectal carcinogenesis. In fact, dif-
ferent epidemiological characteristics, etiology,
pathogenesis and clinical behavior have been reported for
different anatomical sites of colorectal cancer [49,50], this
latter group suggesting that carcinogenesis within the dis-
tal colon was associated with bulky-adduct-forming (BAF)
agents and that these DNA lesions were repaired through
NER pathways. In 2001, Hong et al. [51] also found that
much more DNA-repair and apoptosis activity occurred in
the distal rather than the proximal colon for the rat
azoxymethane carcinogenesis model. Taken together,
these observations support the notion that insufficient
DNA-repair capacity could contribute to the risk of cancer
associated with exogenous carcinogen exposure.
To the best of our knowledge, this study is the first to
report on XRCC1, XRCC3  and XPD  polymorphisms in
relation to the risk of colorectal cancer for the Taiwanese
population. Our results suggest that genetic polymor-
phisms of the XRCC1, XRCC3 and XPD genes, particularly
in combination, may be associated with an individual's
susceptibility to colorectal cancer. Acknowledging the rel-
atively limited sample size in the subgroups for the low
allelic frequencies, further studies incorporating a larger
sample size and/or another ethnic population are needed
to confirm the genetic role of DNA-repair mechanisms as
regards colorectal cancer susceptibility.
Conclusions
Our results suggest that DNA-repair pathways may simul-
taneously modulate the risk of colorectal cancer for the
Taiwanese population, and, particularly for rectal cancer
and younger patients.
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